Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Cyclophosphamide

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44338   clinical trials with a EudraCT protocol, of which   7368   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    790 result(s) found for: Cyclophosphamide. Displaying page 1 of 40.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2004-003731-31 Sponsor Protocol Number: 2005 PK 02 Start Date*: 2005-03-09
    Sponsor Name:University Hospitals of Leiceter NHS Trust
    Full Title: Pharmacogenetics and metabolism of cyclophosphamide in paediatric non-Hodgkin’s Lymphoma
    Medical condition: non-Hodgkin's Lymphoma
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2005-003931-40 Sponsor Protocol Number: BRD/05/95 Start Date*: 2006-04-20
    Sponsor Name:University College London
    Full Title: Phase ll Trial of Fludarabine & Cyclophosphamide followed by Thalidomide for Angioimmunoblastic Lymphoma
    Medical condition: Angioimmunoblastic T-cell lymphoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2005-000656-33 Sponsor Protocol Number: 507088 Start Date*: 2005-06-06
    Sponsor Name:Royal Devon and Exeter NHS Foundation Trust
    Full Title: A Phase I/II Study of Sirolimus (Rapamune TM) in Combination with Cyclophosphamide and Dexamethasone in Relapsed Myeloma
    Medical condition: Plasma Cell Myeloma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-024515-13 Sponsor Protocol Number: VU-007 Start Date*: 2011-03-22
    Sponsor Name:VU University Medical Center
    Full Title: Phase 1-2 study of everolimus and low-dose oral cyclophosphamide in patients with metastatic renal cell cancer.
    Medical condition: Metastatic renal cell cancer
    Disease: Version SOC Term Classification Code Term Level
    12.1 10050513 Metastatic renal cell carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2005-002247-86 Sponsor Protocol Number: 602030 Start Date*: 2005-12-05
    Sponsor Name:Royal Devon and Exeter NHS Foundation Trust
    Full Title: Peripheral Blood Stem Cell Mobilisation with Cyclophosphamide and Methylprednisolone in Patients with Myeloma and Indolent Lymphoma– a prospective single arm study with historical controls
    Medical condition: Plasma cell myeloma Non hodgkins lymphomas - follicular lymphoma, Mantle cell lymphoma, Lymphoplasmacytic lymphoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2006-001965-41 Sponsor Protocol Number: BRD/06/052 Start Date*: 2008-09-05
    Sponsor Name:University College London
    Full Title: Phase III, multicentre, randomised study of fludarabine/cyclophosphamide combination with or without Rituximab in patients with untreated mantle cell lymphoma
    Medical condition: Mantle Cell Lymphoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2009-011406-42 Sponsor Protocol Number: P071221 Start Date*: 2010-02-02
    Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
    Full Title: Etude randomisée prospective comparant l'effet du cyclophosphamide et du mycophénolate chez les enfants atteints de néphrose corticodépendante
    Medical condition: enfants atteints de néphrose corticodépendante
    Disease: Version SOC Term Classification Code Term Level
    8.1 10029161 NEPHROSE PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-004897-77 Sponsor Protocol Number: 0068-20 Start Date*: 2021-09-13
    Sponsor Name:Intas Pharmaceuticals Ltd.
    Full Title: A multicentric, open label, balanced, randomized, two-stage, two-treatment, two-period, two-sequence, crossover, multiple oral dose, comparative bioavailability study of cyclophosphamide powder for...
    Medical condition: Adult female patients with breast cancer.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    Population Age: Adults Gender: Female
    Trial protocol: Outside EU/EEA
    Trial results: (No results available)
    EudraCT Number: 2008-008676-13 Sponsor Protocol Number: CCR3164 Start Date*: 2009-08-04
    Sponsor Name:The Royal Marsden NHS Foundation Trust
    Full Title: A Phase II Study Of Sunitinib And Low Dose Metronomic Cyclophosphamide In Advanced Renal Cell Cancer
    Medical condition: Metastatic Renal Cell Carcinoma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10050513 Metastatic renal cell carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2004-001263-22 Sponsor Protocol Number: YMB1002-02 Start Date*: 2005-01-07
    Sponsor Name:YM Biosciences Inc
    Full Title: A Phase III study of DPPE (Temilifene) combined with Epirubicin and Cyclophosphamide versus Epirubicin and Cyclophosphamide alone as First – line Treatment in Metastatic/Recurrent Cancer
    Medical condition: Metastatic and/or recurrent cancer of the breast
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: EE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-004242-42 Sponsor Protocol Number: J1S-MC-JV01 Start Date*: 2021-05-12
    Sponsor Name:Eli Lilly and Company
    Full Title: A Randomized, Open-Label Phase 2 Study Evaluating Ramucirumab in Pediatric Patients and Young Adults with Relapsed, Recurrent, or Refractory Desmoplastic Small Round Cell Tumor.
    Medical condition: Desmoplastic small round cell tumour (DSRCT)
    Disease: Version SOC Term Classification Code Term Level
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10064581 Desmoplastic small round cell tumour PT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: FR (Completed) DE (Completed) ES (Ongoing) BE (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-004278-41 Sponsor Protocol Number: 01081 Start Date*: 2010-04-19
    Sponsor Name:Institut Jules Bordet
    Full Title: A phase II study of doxorubicin, cyclophosphamide and vindesine with valproic acid in patients with refractory or relapsing small cell lung cancer after platinum derivatives and etoposide.
    Medical condition: This is a prospective phase II study investigating well-known chemotherapeutic (doxorubicin, cyclophosphamide, vindesine) and antiepileptic (valproate) agents, in combination, for the treatment of...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-003610-15 Sponsor Protocol Number: RITUXVAS Start Date*: 2005-12-15
    Sponsor Name:Cambridge University Hospitals NHS Foundation Trust
    Full Title: An international, randomised, open trial comparing a rituximab based regimen with a standard cyclophosphamide/azathioprine regimen in the treatment of 'generalised' ANCA associated vasculitis.
    Medical condition: Anti neutophil cytoplasmic antibody (ANCA) associated vasculitis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) CZ (Completed) SE (Completed)
    Trial results: View results
    EudraCT Number: 2008-000709-12 Sponsor Protocol Number: C19562/2037/BC/EU Start Date*: 2008-05-27
    Sponsor Name:Cephalon France
    Full Title: Prospective, Open-Label, Randomized Study of Combination Therapy of MYOCET® Plus Cyclophosphamide and Trastuzumab Versus Free Doxorubicin Plus Cyclophosphamide Alone, Each Followed by Docetaxel and...
    Medical condition: Patients with human epidermal growth factor receptor-2 (HER2) positive stage II or III breast cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10065430 HER-2 positive breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: FR (Completed) BE (Completed) ES (Completed) AT (Completed) NL (Completed) GB (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2006-007082-36 Sponsor Protocol Number: RV178 Start Date*: 2007-10-16
    Sponsor Name:Hellenic Oncology Cooperative Group
    Full Title: A Phase I/II trial of lenalidomide combined with cyclophosphamide and intermediate dose dexamethasone in patients with primary (AL) systemic amyloidosis
    Medical condition: Primary (AL) amyloidosis in untreated patients or patientsw who have failed prior treatments
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Completed)
    Trial results: View results
    EudraCT Number: 2005-004126-56 Sponsor Protocol Number: NUTH-2005-03523 Start Date*: 2006-03-07
    Sponsor Name:Newcastle upon Tyne Hospitals NHS Trust
    Full Title: Observational pharmacokinetic study of doxorubicin and cyclophosphamide in patients with early breast cancer.
    Medical condition: Early breast cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2008-004822-17 Sponsor Protocol Number: 17072008 Start Date*: 2008-12-10
    Sponsor Name:University Medical Center
    Full Title: Bortezomib in combination with continuous low-dose oral cyclophosphamide and dexamethason followed by maintenance in primary refractory or relapsed bortezomib naïve multiple myeloma patients
    Medical condition: Evaluation of the safety and efficacy of bortezomib combined with cyclophosphamide and dexametasone for induction and maintenance in bortezomib naive refractory on relapsed MM, stage II - III.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-000224-27 Sponsor Protocol Number: SSc/CYC/MP Start Date*: 2008-10-15
    Sponsor Name:Newcastle upon Tyne NHS Foundation Trust
    Full Title: Systemic sclerosis associated interstitial lung disease: A longitudinal observational study assessing optimum treatment regimens.
    Medical condition: Systemic Sclerosis associated interstitial lung disease
    Disease: Version SOC Term Classification Code Term Level
    9.1 10042953 Systemic sclerosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2006-002845-36 Sponsor Protocol Number: PK200609 Start Date*: 2006-11-14
    Sponsor Name:Newcastle upon Tyne Hospitals NHS Foundation Trust
    Full Title: Pharmacokinetics and pharmacogenetics of anticancer drugs in infants and young children
    Medical condition: Any childhood cancer.
    Disease:
    Population Age: Newborns, Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2018-004314-17 Sponsor Protocol Number: CFTSp148 Start Date*: 2019-12-30
    Sponsor Name:The Christie NHS Foundation Trust
    Full Title: The CAPER study: A Phase Ib clinical trial of Cyclophosphamide And PEmbrolizumab in metastatic Renal cell carcinoma (CAPER Trial)
    Medical condition: Metastatic renal cell carcinoma with clear cell component
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004864 10080007 Clear cell renal cell carcinoma metastatic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 26 04:06:27 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA